This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Curacle Co., Ltd., Gwangju Institute of Science and Technology, Korea Advanced Institute of Science and Technology. Active years: 2022.
Company Filing History:

Years Active: 2022
Title: Ajin Lim - Innovator in Pharmaceutical Composition
Introduction
Ajin Lim is a notable inventor based in Daejeon, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of inhibitors that target specific metabolic pathways. His work has the potential to impact the treatment of various disorders.
Latest Patents
Ajin Lim holds a patent for a novel tryptophan hydroxylase inhibitor and a pharmaceutical composition that includes this compound. The invention is particularly noteworthy for its excellent inhibitory effect on TPH1, which is crucial for the prevention and treatment of disorders related to TPH1 activity. This includes metabolic disorders, cancer, and issues related to the digestive and cardiovascular systems. Notably, the inhibitor shows promise in treating inflammatory bowel disorders, making it a valuable addition to therapeutic options in this area.
Career Highlights
Throughout his career, Ajin Lim has been associated with prestigious institutions such as the Korea Advanced Institute of Science and Technology and Curacle Co., Ltd. His work in these organizations has allowed him to advance his research and contribute to innovative solutions in healthcare.
Collaborations
Ajin Lim has collaborated with notable colleagues, including In-Kyu Lee and Eun Jung Bae. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his inventions.
Conclusion
Ajin Lim's contributions to the field of pharmaceuticals, particularly through his patent on a tryptophan hydroxylase inhibitor, highlight his role as an innovator. His work has the potential to significantly improve treatment options for various disorders, showcasing the importance of innovation in healthcare.